Guardian Capital LP cut its position in AstraZeneca plc (NYSE:AZN) by 1.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 162,778 shares of the company’s stock after selling 3,200 shares during the quarter. Guardian Capital LP’s holdings in AstraZeneca were worth $5,515,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of AZN. Janney Montgomery Scott LLC increased its position in AstraZeneca by 7.4% during the 3rd quarter. Janney Montgomery Scott LLC now owns 306,060 shares of the company’s stock worth $10,369,000 after purchasing an additional 21,022 shares in the last quarter. Valeo Financial Advisors LLC acquired a new position in AstraZeneca during the 3rd quarter worth approximately $133,000. Ladenburg Thalmann Financial Services Inc. increased its position in AstraZeneca by 9.3% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 33,983 shares of the company’s stock worth $1,152,000 after purchasing an additional 2,895 shares in the last quarter. Continental Advisors LLC increased its position in AstraZeneca by 29.4% during the 3rd quarter. Continental Advisors LLC now owns 103,300 shares of the company’s stock worth $3,500,000 after purchasing an additional 23,500 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in AstraZeneca by 103.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after purchasing an additional 621,831 shares in the last quarter. Institutional investors own 14.75% of the company’s stock.
Shares of AstraZeneca plc (AZN) opened at $33.42 on Wednesday. AstraZeneca plc has a 1-year low of $26.51 and a 1-year high of $35.60. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09. The firm has a market cap of $83,858.58, a P/E ratio of 7.90, a price-to-earnings-growth ratio of 3.01 and a beta of 0.72.
AstraZeneca (NYSE:AZN) last posted its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The firm had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the firm posted $1.32 EPS. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. equities analysts predict that AstraZeneca plc will post 1.87 earnings per share for the current fiscal year.
AZN has been the subject of a number of research analyst reports. BMO Capital Markets initiated coverage on shares of AstraZeneca in a research report on Wednesday, September 6th. They set an “outperform” rating and a $38.00 price objective for the company. Sanford C. Bernstein upgraded shares of AstraZeneca from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $30.00 to $39.00 in a research report on Friday, September 22nd. Natixis upgraded shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 6th. Argus reiterated a “buy” rating and set a $35.00 price objective on shares of AstraZeneca in a research report on Friday, September 1st. Finally, Citigroup upgraded shares of AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the stock. AstraZeneca presently has a consensus rating of “Hold” and an average price target of $34.20.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://ledgergazette.com/2017/12/13/guardian-capital-lp-has-5-52-million-stake-in-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.